Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
LINE-1 retrotransposon endonuclease (L1-EN)
- Target
- L1-EN
- Molecular classification
- Enzyme, Endonuclease
01
Overview
The LINE-1 retrotransposon endonuclease (L1-EN), specifically the endonuclease domain of ORF2p, is an enzyme responsible for initiating the retrotransposition of LINE-1 elements. It catalyzes a site-specific single-strand nick in genomic DNA, providing a free 3' hydroxyl group that serves as a primer for reverse transcription. L1-EN activity contributes to genomic instability, insertional mutagenesis, and DNA damage, playing a role in diseases such as cancer and aging. Small molecule inhibitors have been developed to target L1-EN, offering potential therapeutic avenues for conditions associated with aberrant LINE-1 activity.
- Other names
- ORF2p endonuclease domainL1 endonucleaseLINE-1 EN
02
Mechanism of action
Inhibition of endonuclease activity, preventing DNA nicking and subsequent retrotransposition
03
Biological functions
DNA cleavageTarget-site primed reverse transcription (TPRT) initiationGenome integration
04
Disease associations
CancerAgingInflammationGenomic instability
05
Safety considerations
Potential for off-target effects due to endonuclease activity on other genomic regions.Unintended consequences of inhibiting L1 activity on normal cellular processes.
Beyond the preview
Go deeper on LINE-1 retrotransposon endonuclease (L1-EN).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LINE-1 retrotransposon endonuclease (L1-EN).